
    
      This is subsequent clinical trial of previously published pooled analysis of the REAL-LATE
      and the ZEST-LATE Trial, in which nonsignificant higher trend for increased rate of death
      (all-cause and cardiac), myocardial infarction, or stroke in the dual antiplatelet therapy
      group compared to the aspirin monotherapy group was noted.
    
  